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INTRODUCTION 
The discovery that a number of enzymes exist in multiple forms 
called isozymes (73) or, more recently, parent and hybrid enzymes (18), 
and that the composition of a given isozyme varies from tissue to 
tissue (124), suggested that the isozymes of tumors might be signifi-
cantly different from those of other tissues. This further suggested 
that an enzyme specific antibody might inhibit the growth of the tumor 
by immunologically inhibiting an essential enzyme of a metabolic path-
way necessary for the growth and development of that tumor. It i.s the 
purpose of thi.s thesis to investigate this hypothesis. 
Aisenberg (l), after making a comprehensive study of the respira-
tion and glycolysis of tumors, concluded that: 
"The energy metabolism of tumors remains such a striking 
metabolic property of tumors that it deserves to be exploited 
chemotherapeutically in the hope that it may indicate a 
specific requirement of the neoplastic cell. This chemothera-
peutic attack could be either through an agent which attacked 
the tumor cells' respiratory mechanism (assuming, for example, 
that the very limited respiratory enzymes of the neoplastic 
cell are just sufficient to maintain it and agents further 
damaging these enzymes would lead to death of the neoplastic 
cell before its normal counterparts) or through an agent which 
attacked the glycolyti.c mechanism (perhaps on the assumption 
that the high rate of glycolysis was uniquely necessary for 
the neoplasti.c process) •11 
I have chosen to take the second approach. 
If the glycolytic pathway is as essential for the growth and 
development of the tumor as has been suggested, then it should be 
possible to inhibit this process without impairing carbohydrate oxi-
dation by blocking the final step, which involves the conversion of 
pyruvate to lactate and the regeneration of oxidized nicotine adenine 
dinucleotide in the presence of lactic acid dehydrogenase. The 
Ehrlich ascites carcinoma has been selected for thi.s study. It is 
particularly suitable because it possesses an unusually high rate of 
glycolysis (118) and it can be obtained relatively free from other 
tissues and cells. It has a relatively rapid rate of growth (55) and 
its growth can be evaluated by cell counts. 
2 
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I. REVIEW OF LITERATURE 
A. Lactic Acid Dehydrogenases, Purification and Properties 
In 1940 Straub (104) first purified and crystallized lactic 
acid dehydrogenase from beef heart muscle and conclusively identifi.ed 
it as a specific enzyme catalyzing the reaction: 
NAD+ +lactic acid NADH + H + pyruvic acid 
Since that time, lactic acid dehydrogenase has been isolated by 
various methods from human heart and liver (86, 87), rabbit muscle 
(10, 99), rat liver (38), rat muscle (58), Jensen sarcoma (58), and 
pig muscle (50). 
The extent of the purification of these lactic acid dehydrogenases 
from aqueous tissue extracts varied from 26 fold to 350 fold. However, 
when the physical properties of the purified lactic acid dehydrogenases 
were compared, they all appeared to possess the same degree of purity. 
Upon ultracentrifugal analysis each lactic acid dehydrogenase sedi-
mented as a single peak. The sedimentation coefficients (s20 ) varied 
from 6.36 to 7.6 x l0-13 seconds (38, 44, 58, 74, 84, 87). However, 
this variation must be considered insignificant because the s20
1 s were 
measured in different buffers at different ionic strengths and were not 
extrapolated to infinite protein dilution. The molecular weights (MW) 
which were calculated from the ultracentrifugal data, 126,000 - 140,000, 
varied less than the sedimentation coefficients, and together they in-
dicated that the lactic acid dehydrogenase molecules from different 
tissues were approximately the same size. 
Monodispersity in a centrifugal field alone is not sufficient 
evidence for the establishment of molecular homogeneity. It must be 
supported by electrophoretic data. In the initial studies on beef 
4 
heart lactic acid dehydrogenase (74) using the Ti.selius apparatus, the 
active enzyme was represented by a single electrophoretic peak con-
taining 85% of the total protein. Nielands (82, 83) reinvestigated the 
electrophoretic mobility of this enzyme preparation and, contrary to 
Meister (74), discovered the existence of two electrophoretically 
separable proteins with lactic aci.d dehydrogenase activity, i.e., 
isozymes. The faster anodally moving fraction, A, differed from C by 
binding more NADH2 per mg. of protein and by having a larger turnover 
number. 
Subsequent studies on rat (123), rabbit (96, 97), swine (123), 
bovine (37, 123), and human (96, 97) tissue extracts using the starch 
gel electrophoresis method of Smithies (103) showed that three to five 
lactic acid dehydrogenase isozymes existed in each species of animal, 
and that the lactic acid dehydrogenase isozymes characteristic of a 
given species were distributed differently in each organ with respect 
to the number of isozymes and the amount of activity of each isozyme. 
From the combined electropherogram of the lactic acid dehydrogenases 
of rabbit and human tissues, Plagemann ::.!:. al. ( 97) observed, i.n each 
species, a uniform increment in the electrophoretic mobilities of the 
lactic acid dehydrogenases and a uniform change in their response to 
varying pyruvate concentrations. They also observed a uniform increment 
in the percentage of inhibition of some of the rabbit isozymes by rooster 
antibody against the slowest anodally moving isozyme. Finally, a si.mi.lar 
correlation between sulfite inhibition and electrophoretic mobility was 
reported by Wieland and Pfleiderer (123) for rat lactic acid dehydro-
genases. Together these facts suggest that some uniform chemical 
change exists between the different lactic acid dehydrogenases of a 
given animal species. 
The exact nature of this uniform chemical change still eludes us. 
However, after the current evi.dence was examined, i.t was obvious that 
this difference was not due to the presence of varying amounts of DNA, 
RNA, or mononucleoti.des, since the isozyme pattern was not altered 
after treatment with RNAase, DNAase, alkaline phosphatase (97) or pro-
tamine (l2J). Having eliminated contamination by these substances, 
three alternative explanations remained. The variation in electro-
phoretic mobility could have been the result of the separation of 
several forms of the enzyme cofactor complex; it could have been the 
result of differences in amino acid sequence; or it could have been a 
combination of both factors. 
In 1952, Chance and Neilands (19) reported that rabbit skeletal 
muscle lactic acid dehydrogenase A bound, one to four moles of NADH2 
per mole of enzyme. Four years later, Takenaka and Schwert (105) 
suggested that the same lactic acid dehydrogenase A bound a maximum 
of approximately four moles of NAD per mole of enzyme to four sulf-
hydryl groups (129) on the enzyme surface. They further suggested 
that four moles of NADH2 could also be bound to these four sulfhydryl 
groups (130). These conditions permit the existence of fourteen pos-
sible enzyme cofactor complexes as well as the free enzyme. If the 
electrophoretic mobilities of these complexes were examined at pH 8.5, 
the pure enzyme (E) theoretically would probably migrate most rapidly 
toward the anode, while the most highly positive substituted complex 
E-4 NAD would migrate most slowly. The evidence for thi.s hypothesis 
5 
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is as follows: The bovine heart muscle lactic acid dehydrogenase A (83), 
when titrated, accepted four NAD molecules (105), or 4 NADH2 molecules 
(130). Therefore its form was E. It was also the fastest anodally 
migrating component. Furthermore, the more slowly mi.grating bovine 
muscle lactic acid dehydrogenase C had a 280/255 ratio, which was 20% 
lower than that of lactic acid dehydrogenase (83). If one considers 
that the complexing of one mole of NAD with one mole of glyceraldehyde 
3 phosphate dehydrogenase reduces the 280/255 ratio 19% (109), then it 
is reasonable to conclude that lactic acid dehydrogenase C is either 
E-NAD or E-NADH2• The existence of one of these two more slowly mi-
grating forms of lactic acid dehydrogenase in crude tissue extracts was 
confirmed by Wieland and Pfeiderer (123) using starch gel electrophoresis. 
Furthermore, the possible existence of a third :l_acti.c acid dehydrogenase 
was also indicated. 
Finally, the bisulfite ion, which reacts wi.th NAD to give the 4 
pyridyl adduct, i.nhibited the activity of the faster anodally movi.ng 
lactic acid dehydrogenase more than that of the slower migrating lactic 
acid dehydrogenases (123). If one postulates that all four binding 
sites are not equally active, then a graded inhibition would be observed 
if the NAD so
3
H were bound more strongly to some sites and less strongly 
to others. 
In 1962, Cahn et al. (18) demonstrated that the heterogeneity 
observed in lactic acid dehydrogenase preparations was the result of 
the variation in the composi.tion of the lactic acid dehydrogenase 
molecule. Based upon the facts that lactic acid dehydrogenase binds 
four moles of nicotine adenine dinucleotide, that i.t can be dissociated 
7 
into four protein molecules of 31,000 MW (3), and that in chromato-
graphic fingerprints of tryptic digests there are only one quarter the 
number of argenine plus lysine spots as there are residues of the amino 
acids in the entire lactic acid dehydrogenase molecule, the following 
hypothesis was formulated: lactic acid dehydrogenase is a tetramer 
composed of four protein molecules, each with a molecular weight 31,000. 
The fastest anodally migrating enzyme is composed of four identical 
units of one protein, and the slowest, of four identical units of a 
different protein. These are called parent enzymes. The three inter-
mediate mi.grati.ng enzymes are mixtures of the two proteins: AAAB, AABB, 
ABBE. These are called hybrid enzymes. This would accuunt for the 
fact that only a maximum of five forms of lactic acid dehydrogenase, 
have been isolated in any tissue of any animal. This would further 
account for the uniform regular variation in the immunological, physical, 
and biochemical properties of the lactic acid dehydrogenase enzyme forms. 
Furthermore, if each subunit possesses one NAD binding site, and 
subunit B binds NAD so3H2 more strongly than A, then a graded inhibition 
would be obtained in which 4B was inhibited to the greatest degree. 
This would further agree with the observed increasing pyruvate inhibi-
tion at high levels of pyruvate, since pyruvate is bound to the enzyme 
only through NADH2 (43, 90, 91, 105, 129). 
The activity of each isozyme also appeared to be inhibited to a 
different degree by a given anti-lactic dehydrogenase (85, 88, 97). 
Plagemann et al. (97) reported that the fastest anodally moving isozyme, 
LD5, was least inhibited by the partially puri.fied antibody to LD1, 
whereas the slower moving lactic acid dehydrogenases (LD4, LD3, LD2, 
8 
and rn1 ) were progressively more inhibited. Mansour (71), using rabbi.t 
muscle lactic acid dehydrogenase purified by the method of Kornberg and 
Pricer (56), and a partially purified anti-rabbi.t lactic acid dehydro-
genase from roosters (72), observed that a decrease i.n substrate concen-
tration in the incubation mixture resulted in a decreased inhibition of 
the rabbit muscle lactic acid dehydrogenase by partially purified 
rooster antiserum. If these results are interpreted i.n terms of the 
hybrid enzyme hypothesis which has been suggested, then it appears that 
the antiserum requires substrate and cofactor for maximum action, and 
that it is more specific for one subunit than for the other. The possi-
bility exists that the antiserum reacts partially with the active site 
as well as having a preference for one of the subunits. 
The fact that NADH2 partially inhibits the immunological reaction 
of schistosome lactic acid dehydrogenase with its antiserum (72) and 
of rabbit plasma lactic acid dehydrogenase with anti-LD1 serum (97) 
further substantiates the fact that the active center plays a role in 
the reaction even though it is not the only requirement of the immuno-
logical reaction. The inhibition of the antibody reaction with 
schistosome lactic acid dehydrogenase and rabbit plasma lactic acid 
dehydrogenase by NADH2 and the enhancement of the antibody rabbit muscle 
lactic acid dehydrogenase reaction by NADH2 might suggest that, on one 
hand, the antibody reacts with the subunits with a low binding ability, 
and on the other hand, wi.th the subunit of high binding ability. 
Finally, Nisselbaum and Bodansky (88) have reported the absence 
of an inhibitory effect of NADH2 and pyruvate on the anti.body enzyme 
reaction. However, the antibody which they used was not purified, and 
9 
the dialyzable serum factor which was reported by Plagemann et al. (96) 
may have masked any possible NADH2 (96) or pyruvate (58) inhibition. 
The hybrid enzyme hypothesis adequately explains the existence of 
different forms of enzymes catalyzing the same reaction in a given 
tissue. However, the recent evidence of Wieland and Pfleiderer (l24, 
l25) demonstrated that electrophoretically identical isozymes from two 
different tissues differed in amino acid composition. The exact points 
of variation in the amino acid sequence are still unknown, but immuno-
logical evidence suggests that these variations are much more subtle than 
those occurring in the amino acid sequence of the lactic acid dehydro-
genases of different species of animals (72, 96). The fact that this is 
a variation in the amino acid sequence and not in composition is suggested 
by the absence of any large variation between rabbit, pig, and rat lactic 
acid dehydrogenases in total amino acid composition (l24). 
B. Glycolysis in Tumors and Normal Tissues 
The origin of the concept of glycolysis dates back to the beginning 
of a long series of papers by Dr. Warburg on the manometric technique and 
the applicati.on of thi.s technique to the study of cell metabolism. The 
results of the application of this technique led to the generalization 
that human and animal tumors almost without exception, exhi.bit a hi.gh 
N 
rate of anaerobic glycolysis. In animal tumors, this value (QC~ ) was 
2 
consistently in excess of 20, and in ascites tumors, the purest form of 
tumor known, it was between 30 and 80. 
In addition to a high rate of anaerobic glycolysis, tumor tissues 
also possessed the abi.lity to perform glycolysis under aerobic conditions 
at rates higher than those observed for normal tissues. However, the 
10 
values for aerobic glycolysis were not nearly as consistent as those for 
the anaerobic form. (See extensive tables in Aisenberg) (1). 
Since the early work of Warburg, literally hundreds of publications 
have appeared confirming his results. These have been summarized by 
Aisenberg (l) and by Busch (16) in their monographs on the biochemical 
properties of the cancer cell. There are only a few exceptions to the 
Warburg generalization. These are embryonic cells in tissue culture 
(64, ll9), viral skin lesions (23), jejunal mucosa (26), renal medulla 
(25), retina (57, 120), myeloid bone marrow and tonsil (36, 120, 121). 
The last two normal tissues probably derived their high rate of gly-
colysis from the cells of the leukocyte series which are present in 
relatively large numbers and which also possess a high rate of glycolysis 
(36). The high rate of glycolysis in mouse and rat embryonic tissue may 
be explained by the predominance of the muscle type enzyme which is not 
very sensitive to substrate inhi.bition and which would permit the for-
N2 
mation of large amounts of lactic acid; therefore a higher QCO (33). 
2 
This requires further confirmation, however. 
The most rigid test of the Warburg generalization is the comparison 
of a homologous series of normal and neoplastic ti.ssues. The first, and 
one of the more complete studies was made on rat liver undergoing butter 
yellow carcinogenesis (13, 14). The data indicated that the neoplastic 
N 
liver possessed a QC~ six to twelve times that of both normal and re-
2 
02 
generating rat li.ver and a QCO two to four times greater. A second 
2 
report (27) confirmed the values for rat liver neoplasms but indicated 
that no increase occurred in spontaneous hepatomas. However, the mouse 
hepatomas were much more histologically and biochemically (urea, aceto-
ll 
acetate, and carbohydrate synthesis) similar to normal mouse liver 
than the azo dye rat tumors were to normal rat liver (27). The ~ncreased 
anaerobic glycolysis of preneoplastic liver remains questionable, since 
there was a large variation in the values for normal liver (13, 54, 92, 
102, 122). Detailed studies (92, 122) on the effect of various experi-
mental conditions on the rate of anaerobic glycolysis of normal liver 
indicate that lactate formation was dependent upon the potassium, phos-
phate, and bicarbonate content of the medium and upon the glycogen con-
tent of the liver. Thus it is difficult to assess the reports which 
cite small changes in the aerobic and anaerobi.c metabolism of preneo-
plastic tissues. 
A second particularly interesting observation was that normal and 
regenerating rat livers had similar aerobic and anaerobic glycolytic 
rates (61), indicating that caution must be exercised in expecting simple 
correlations between energy metabolism and growth. 
Studies with 3-methylcholanthrene-induced mammary carcinomas (100) 
support the results obtained with the azo-dye induced liver tumors. The 
mammary tumors possessed a high rate of aerobic and anaerobic glycolysis, 
whereas normal lactating and non-lactating glands displayed low rates of 
lactate production. This difference was accompanied by a large increase 
in lactic acid dehydrogenase, a smaller one in isocitric acid dehydro-
genase, and a consistently large decrease in malic dehydrogenase. 
Studies with human skin and endometrium (27, 28) are consistent 
with the liver experiments (13, 14). Carcinoma of the vulva displayed 
a high anaerobic glycolytic rate, whereas normal skin of the vulva has 
a rate similar to that of normal liver. Leukoplakic skin (considered 
to be a preneoplastic condition) displayed only a modest amount of 
anaerobic glycolysis. 
12 
The results of experiments with several rabbit carcinomas (ll, 23, 
53) and normal rabbit skin (53) also support the data on the azo-dye 
liver tumors (13, 14). Several chicken viral ski.n lesions (23) also 
possessed high rates of anaerobic glycolysis, but the results on the 
Shope panilloma, the precursor of the V 2 carcinoma, di.sagree (ll, 53), 
as did those for preneoplastic liver (13, 54, 92, 102, 122). 
Lymph nodes from mice with spontaneous and transmitted lymphatic 
leukemia (15, 110-116) showed a small but significant i.ncrease over 
normal lymph nodes in aerobic and anaerobic glycolysis. The trans-
mitted leukemias showed a larger increase in anaerobic lactate produc-
tion than the spontaneous ones. The increases in aerobic glycolysis 
were not as consistent as those for anaerobic glycolysis. These re-
sults have also been extended to preleukemic, leukemic, and leukemoid 
lymph nodes, liver, and spleen (15). The metabolism of the normal 
leukocytes, when compared to the leukocytes of chronic lymphocytic and 
chronic myelocytic leukemias, was the opposite of that observed for 
other homologous systems. Both in the intact form (68) and as a homog-
enate (7-9) the normal cells showed a higher rate of aerobic and 
anaerobic glycolysis when compared to that of the neoplastic cells. 
Beck (4-6) has suggested that this phenomenon was the result of a 
parti.cular ly low level of hexokinase in the leukemic cells. 
Studies on glycolysis by embryonic cells, as well as by cultures 
of normal and neoplastic cells also appear to contradict the results 
which have just been outlined. Cultures of chick fibroplasts (60, 119) 
and embryonic heart ( 119) di.splayed both high aerobic and high anaerobic 
13 
glycolysis. Explants of other chick embryonic tissues (95, 127, 128) 
displayed a significantly high aerobic glycolysis. Cultures of human 
embryonic and malignant tissues (64) also displayed a high rate of 
aerobic glycolysis, the rates for embryonic tissues being greater than 
those for malignant tissues. Warburg, on the other hand, concluded that 
the intact embryo when carefully handled displayed no aerobic glycolysis 
(117). Most recently, cultures of malignant and non-malignant rat 
lymphoblasts have also been shown to possess high glycoli.tic rates, the 
malignant rates being slightly higher (46). 
The elucidation of the significance of these contradictions re-
quires further experimentation. Leslie et al. (64) showed that the 
values obtained for the respiratory and glycolytic rates of cultured 
neoplasms and embryonic tissues was dependent upon the culture medium 
used. Furthermore, the glycolytic rate for the first two to three hours 
was very high, and it subsequently became reduced to a poi.nt where some 
of the lactic acid was utilized by the cell. Thus the removal of the 
cells to an artificial maintenance medium and the measurement of the 
glycolytic rates at various times can lead to serious misinterpre-
tations and contradictions. It has also been suggested (l) that these 
contradictions may be due to the selection from the explant of a cell line 
wi.th a hi.gh aerobic glycolytic rate, a modification in metabolism brought 
about by adaption to tissue culture or an artifact resulting in the large 
medium volume to tissue volume ratio. Finally, several investigators 
(33, 73) have shown that the lactic acid dehydrogenase of some vertebrate 
embryonic tissues undergoes a transformation from the pure muscle type 
enzyme in the early embryo to the heart type in the adult. The muscle 
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type is less inhibited by the substrate, permitting a hi.gher rate of 
glycolysis for a longer period of time and thus allowi.ng a greater 
accumulation of lactic acid in the early peri.ods of incubation. In 
combination with the total lactic acid dehydrogenase concentration, this 
could conceivably account for some of the large variations which have 
been observed in the glycolytic rates of normal, embryoni.c and neo-
plastic tissues. 
c. Glycolysis in Homogenates and Extracts 
The apparent universality of a high anaerobic glycolytic rate in 
tumors led Meyerhof and LePage, simultaneously, to attempt to define 
this property in terms of one or more biochemical lesions by studying 
the glycolytic metabolism of tissue homogenates and extracts. Meyerhof, 
working with brain (75, 76, 79) and several transplantable rat and mouse 
tumors (77, 78) concluded that the active glycolysis of free glucose was 
the result of a fine balance between ATPase and hexokinase, which uti-
lized ATP. Lack of ATP·ase resulted in reduced gJycolysis due to low 
inorganic phosphate and low ADP, while excess ATPase reduced the level 
of ATP and consequently inhibited the hexokinase and gJycolysis. Both 
brain and tumor homogenates possessed large amounts of ATPase, but the 
brain enzyme was parti.culate and the tumor ATPase was cytoplasmic. 
Removal of the ATPase activity either by centrifugation or by ATPase 
inhibitors resulted in high glycolytic rates for all tissues. The 
location of the glycolytic enzymes in the particle-free cytoplasmic 
fraction by Meyerhof was confirmed by LePage (63), who also demonstrated 
that the concentration of organic phosphates in normal and neoplastic 
tissues were of the same order of magnitude (61). 
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In a later seri.es of experiments (62), LePage searched for factors 
which regulated anaerobic glycolysis in normal and neoplastic tissue 
homogenates. Using glucose, hexose-diphosphate, glucose-6-phosphate, 
and fructose-6-phosphate, he demonstrated that all tissue homogenates 
(heart, skeletal muscle, diaphragm, kidney, liver, brain, and three rat 
carcinomas) utilized the phosphorylated sugars, but only brain and tumor 
were able to utilize glucose. Since all tissues utilize glucose in vivo, 
LePage suggested that this was some type of in vitro functional hormonal 
block of hexokinase. However, the nature of this block has not been 
identified yet. 
More recently, Wu and Racker (134), working with Ehrli.ch ascites 
tumor, also confirmed the enzyme distribution described by Meyerhof and 
the fact that the hexokinase step was one of the rate-controlling steps 
in the glycolytic cycle. They also showed that 60% of the hexokinase 
was located in the mitochondria and that phosphofructokinase, aldolase 
and glyceraldehyde-3-phosphate dehydrogenase were also partially rate-
controlling. Of particular importance was the fact that homogenates of 
fortified extracts displayed a glycolytic rate which was three to four 
times that of the i.ntact ascites cell. Furthermore, the ascites cell 
glycolytic rate could be partially improved only by increasing the 
extracellular inorganic phosphate concentration (48, 134). Thus it 
again appears that the composition of the medium, particularly the 
external concentration of phosphate, is most critical, and that the 
internal enzyme concentrations are adequate. 
In summary, there are at least three possible metabolic differences 
between normal and neoplastic tissues in the glycolyti.c cycle per ~· 
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Not one of these has been shown to be exclusively operative, and on the 
basis of Wuts evidence that the external concentration of inorganic 
phosphate is the controlling step, the pertinence of the data acquired 
with homogenates must be challenged. Furthermore, the absolute require-
ment of the anaerobic glycolytic metabolism for the growth and repro-
duction of neoplastic tissue must be demonstrated. 
D. The Role of Glycolysis i.n Overall Metabolism 
Several investigators (24, 70, 80) studying the rate of incorporation 
of P32 into the phospholipid, phosphoprotein, and nucleic acids of tumors 
and normal tissue demonstrated that, in the presence of glucose, P32 was 
incorporated into tumor tissue equally well under aerobic and anaerobic 
conditions. In the absence of glucose, P32 incorporation was drastically 
reduced under anaerobic conditions (24, 70, 80). Under aerobic con-
ditions, uncoupling agents such as 2-4 dinitrophenol inhibited p32 incor-
poration in the absence of glucose but not in its presence (23a). In 
normal tissues (liver and kidney) the P32 incorporation was reduced 40-
50% under anaerobic conditions either in tbe presence or absence of 
glucose (70). The implication of these results is that the tumor can 
utilize the energy from anaerobic glycolysis more efficiently than normal 
tissues. However, these experiments lacked a comparison to experiments 
on tissues with a high rate of anaerobic glycolysis. 
Quastel and Bickis (98) have circumvented this criticism in an ex-
tensive and thorough study of the relationship of energy metabolism to 
protein synthesis. Their index of measurement was the incorporation of 
c14 glycine into the tissue protein of cell suspensions or tissue slices. 
They studied two ascites tumors, including the Ehrlich ascites tumor; 
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four solid tumors; rat and chick embryo; and ten normal tissues including 
rat kidney medulla, rat brain, rat thymus, and cattle reti.na. The re-
sults of these experiments supported the P32 experiments by demon-
strating that in the presence of glucose, Ehrlich ascites cells could 
incorporate c14 glycine equally well under aerobic or anaerobic con-
ditions, but in the absence of glucose, incorporation occurred only under 
aerobic conditions. The other tumors and the embryonic tissues, in the 
presence of glucose, also incorporated large amounts of c14 glycine under 
either aerobic or anaerobic conditions. In contrast to this, 
tissues synthesized much less protein from c14 glycine in the 
normal 
presence 
of glucose under anaerobic conditions but not under aerobic conditions. 
This was true for both tissues which had a 
N 
high QC~ and those with a 
2 N2 
low Q00 • Additional studies comparing the glycolytic ability of em-2 
bryonic and neoplastic tissues revealed that in the presence of glucose 
and under aerobic conditions, a respiratory inhibitor such as malonate 
had much less effect on the incorporation of c14 glycine into the tumor 
than into the embryo. In the absence of glucose, malonate almost com-
pletely inhibited glycine incorporation into the tumor, whereas it only 
partially inhibited glycine incorporation into embryonic tissue. The 
glycolysis of the tumor was similarly affected by bilirubin and by 2-4 
dinitrophenol. 
In summary, this evidence suggests that neoplastic tissue is able 
to utilize effectively both glycolytic and respiratory energy, whereas 
normal tissue cannot utilize glycolytic energy effectively. It is also 
evident that neoplastic tissue is able to continue its synthetic pro-
cesses in the presence of an inhibited respiration or uncoupled oxidative 
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phosphorylation, whereas the synthetic processes of normal and embryonic 
tissue fail under at least one of these conditions. 
E. The Role of Glycolysis in the Growth of Neoplastic Tissues 
It is apparent now that the glycolytic metabolism of tumors, in 
addition to being consistently high, possesses those properties char-
acteristic of normal tissues plus the property of maintaining synthetic 
processes in the absence of respiration. However, the problem of whether 
the glycolytic metabolism is an absolute requirement for the survival and 
reproduction of neoplastic tissues has received little experimental 
attention. The only enzymatic step in the glycolytic pathway which can 
be inhibited without impairing the oxidation of carbohydrate via the 
Embden-Meyerhof pathway is that step which is catalyzed by lactic acid 
dehydrogenase. 
In order to test this hypothesis, a series of halogenated pyruvic 
acids were tested (17), of which fluoropyruvic acid was found to be the 
most effective inhibitor of lactic dehydrogenase. However, it was 
quickly discovered that this substance also inhibited the oxidation of 
pyruvic acid and was therefore useless for testing the above hypothesis. 
Oxamic acid, another potent inhibitor of lactic acid dehydrogenase (90, 
91), has also been used as an in vitro inhibitor of tumor glycolysis 
(93)· Initial studies with the Ehrlich ascites tumor indicated that 
oxamic acid inhibited the lactic acid dehydrogenase of cell homogenates 
and the aerobic and anaerobi.c glycolysis of the intact cell. It was not 
metabolized by the tumor, nor did it inhibit respiration or pyruvic acid 
oxidation at concentrations which inhibited lactic acid dehydrogenase. 
These results stimulated further investigation of the effect of 
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oxamate on cultures of He1a-S3 cells (94). These experiments revealed 
that the growth and reproduction was inhibited by oxamate, and that the 
inhibition could be reversed by pyruvic acid. It was concluded therefore 
that the lactic acid dehydrogenase and the glycolytic pathway was essen-
tial for the growth of the cells. The rapid excretion of oxamate by 
animals precluded the use of this compound as an in vivo antiglycolytic 
agent (107). 
F. The Metabolic Effect of Whole Cell Antisera and the Antineoplastic 
Effect of Particle-Free Cytoplasm Antiserum 
If the lactic acid dehydrogenase step of the glycolytic pathway is 
as essential as the data of Papaconstantinou and Colowick (93, 94) 
indicate, then the development of an antiserum specific for the tumor 
lactic acid dehydrogenase would be highly desirable as a means of con-
firming and extending their results. 
The metabolic effect of the tumor antisera has received relatively 
little attention. Flax (34) demonstrated that rabbi.t anti-Ehrlich 
ascites gamma globulin in combination with complement inhibited tumor 
growth, glucose oxidation, and respiration, but di.d not inhibit succinate 
oxidation. Bickis et al. (12) confirmed these results and showed that 
rabbit anti-Ehrlich ascites serum, in the presence of complement, in-
hibited respiration, glycolysi~and glycine uptake and incorporation. 
In the presence of succinate the respiration was not affected. Histo-
logical data in both studies indicated that the biochemical inhibition 
was associated with (34) or followed by (12) complement dependent 
cytolysis. Studies by Colter et al. (22) extended the results of 
Bickis (12) by demonstrating that anti-ribonucleoprotein serum as well 
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as anti-whole cell serum inhibited amino acid incorporation by Ehrlich 
ascites cells and 6C3HED cells. 
Isolation of the cell fraction from which the neoplastic antigens 
were derived was first attempted by Dulaney et al. (29, 30). However, 
since the lactic acid dehydrogenase is found only i.n the particle-free 
cytoplasmic fraction of the cell (134), this review will be restricted 
to that cell fraction. Of the four reports concerning this subject, two 
merely report the existence of a relatively weak antigen in the particle-
free cytoplasmic fraction (21, 69) and two by Colter et al. report the 
absence of anti-neoplastic activity by an antiserum to pH 4.5 soluble 
fraction of the cytoplasm (20, 22). Horn (47) has made a thorough study 
of the rabbit anti-cell supernatant serum. He demonstrated that this 
antiserum was an effective inhibitor of the growth of the Ehrlich 
ascites cell, and that it was composed of at least two antibodies, one 
of which was complement dependent. Horn also reported that, on the 
basis of systematic absorptions of the antiserum with whole cells or 
mitochondria, the complement dependent antibody was associated with 
common tissue antigens. He implied that the complement independent anti-
body was associated with the soluble proteins. 
The evidence supporting the existence of a separate tumor lactic 
acid dehydrogenase has been summarized in Section A. The only tumor 
lactic acid dehydrogenase which has been isolated is that from the 
Jensen sarcoma (58). This lactic acid dehydrogenase was shown to be 
ki.netically and antigenically identical to rat muscle lactic acid dehydro-
genase. However, the yield was very low and the tumor contained non-
tumor tissue. These factors, in conjunction wi.th the oxamate i.nhibition 
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of glycolysis, the discovery of the hybrid enzymes, and the antigenicity 
of the supernatant fraction of the cell have led to the investigation of 
the similarity of the lactic acid dehydrogenase of the Ehrlich ascites 
tumor, a pure tumor, to that of other tissues and to the development and 
biological testing of an Ehrlich ascites lactic acid dehydrogenase anti-
serum. 
G. The Viral Etiology of the Ehrlich Ascites Carcinoma 
The evidence for the viral etiology of neoplasms is becoming more 
impressive. From Ehrlich ascites tumor alone three leukemia-inducing 
viruses have been isolated: the Friend virus; the Stansly vi.rus, which 
induces reticulum cell sarcomas; and the Graffi virus, which induces a 
myeloid leukemia (81). Although these viruses induce neoplasia, it 
remains questionable whether the Ehrlich ascites tumor is nerely a 
carrier of the virus or the resultant tumor. The only current evidence 
on this aspect is that of Friend (35) in which she demonstrated that a 
rabbit antiserum to the Friend virus would neutralize the virus alone 
or in the cell suspension and reduce the incidence of leukemia in mice. 
She further demonstrated that a vaccine composed of formalinized virus 
conveyed a lasting passive immunity to the mice against the leukemi.a. 
However, this vaccine did not affect the growth and lethality of the 
Ehrlich ascites tumor, the tumor from which the virus was isolated. It 
therefore appears that the Friend virus is merely an intracellular pas-
senger of the Ehrlich ascites carcinoma. 
More recently, a second intracellular agent has been demonstrated 
in a large number of tumors, including the Ehrlich ascites tumor from 
which it was originally isolated (101). This agent was responsible for 
the increase in plasma lactic acid dehydrogenase levels. It was tran-
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missible, passed through Selas 03 filters, was non-dialyzable, and 
was partially sedimented at 100,000 x g. Hence it was apparently a 
virus. It was separated from Moloney leukemia virus by passage through 
rats where the leukemia virus is recovered and the lactic acid dehydro-
genase agent is lost. The lactic acid dehydrogenase agent was isolated 
from tumors of non-viral etiology by x-irradiation of the tumor (P388 
lymphocytic leukemia) with 10,000 RADts total body irradiation (89). 
Finally, Notkins ~ al. (89) demonstrated that the plasma cell 
tumor SS (70429) which was not normally infected with the lactic acid 
agent, could be infected with this agent. He also demonstrated that 
the agent alone caused a four to five-fold increase in plasma lactic 
acid dehydrogenase within 72 hours. The tumor alone caused a ten-fold 
increase. However, the tumor and the agent together increased the 
plasma lactic acid dehydrogenase 88-fold. Thus it appears that the 
tumor enhances the action of the agent or vice versa. With this infor-
mation, we are now obliged to reassess the metabolic evidence concerning 
the relationship of glycolysis to tumor growth. 
During the past year, Tolnai et al. (106) reported the isolation of 
another transmissible agent from Ehrlich ascites cells which produced an 
ascites tumor when injected intraperitoneally. This agent was sensitive 
to ultrasonic treatment and did not pass through bacterial filters. It 
possessed a pH and temperature sensitivity whi.ch was distinctly different 
from that of the Ehrlich ascites cell. The tumor which resulted differed 
from the Ehrlich ascites tumor in that it had 135-155 chromosomes, 
whereas the parent tumor had only 78 chromosomes. It would be interesting 
to compare the antigenic properties of this agent to those of the two 
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tumors. This might lead to a positive illustration of a combined agent 
and tumor cell specific antiserum. 
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II. ElCPERIMENTAL AND RESULTS 
A. Assay of Lactic Acid Dehydrogenase 
All enzymatic assays in which pyruvate was the substrate were per-
formed in a Zeiss spectrophotometer, at room temperature. Lactic acid 
dehydrogenase activity was determined in the following way: To a 
cuvette containi.ng 2. 9 ml. of O.l M sodium phosphate buffer pH 7. 0 was 
added 0.03 ml. of NADH2 (10 mg./ml.) and 0.03 ml. of 0.02 M sodium 
pyruvate. This solution had an optical density of about 0.700 at 340 
millimicrons. The enzyme (0.02 - 0.03 ml.) was then added to the 
cuvette, the solution was mixed and the optical density was read at l) 
second intervals for one minute. The total change in optical density 
was between 0.0)0 and 0.1)0 units per minute. All enzyme dilutions 
were made in 0.01 M Tris-HCl pH 8.). The protein concentration was 
determined by the absorbance at 280 :tq.L. using the extincti.on coefficient 
of bovine muscle lactic dehydrogenase (2.01 x 1o') and by the method of 
Lowry et al. ( 66). 
The enzymatic assays in which lactate was the substrate were per-
formed in a Beckman DKl spectrophotometer at the appropriate wave length 
for each NAD analog (2, 108) in the following way: to a cuvette con-
taining 2.7-2.9 ml. of 0.1 M dibasic potassium phosphate was added 
0.0) ml. cofactor (10 mg. per ml.) and 0.3-0.02 ml. 2.0 M lithium 
lactate. The enzyme, (O.Ol-0.03 ml.) was then added to the cuvette, the 
solution was mixed, and within fifteen seconds the recorder was started 
at a rate of four inches per minute. The velocity of the reaction was 
calculated from the velocity during the first fifteen seconds of the 
recording. 
25 
The NAD analog ratios were calculated according to the method of 
Kaplan et al. (18, 51). The ratios reported in experiment I (Table IV) 
were calculated from rates of analog reduction recorded with the 
Beckman DKl spectrophotometer and the ratios of experiment II were cal-
culated from absorbance readings taken at 30 second intervals using a 
Zeiss Spectrophotometer. 
B. Preparation of Mouse Heart and Skeletal Muscle Extracts 
The heart and hind leg skeletal muscles were excised from a mouse 
killed by cervical flexure. The tissues were weighed, placed in a 
Potter-Elvehjem homogenizer with 0.1 M Tris-HCl buffer pH 7.4 ~ 0.1 at 
0 3 C and homogenized. The homogenate was centrifuged at 105,000 x g, 
and the supernatant solution was used for the determination of the 
JAcPyAD/Thio N&D ratios. The heart muscle solution contained the 
equivalent of 100 mg. of tissue per millili.ter, and the skeletal muscle 
solution the equivalent of 250 mg. per milliliter. 
c. Preparation of Crude Ehrlich Ascites Carcinoma Cell Extract 
The Ehrlich ascites tumor was grown in Swiss-Webster albino mice 
for eleven days, harvested, and the ascitic fluid removed by centri-
fugation at 500 x g. 0 The cells were stored at -10 C. 
All steps which involved the enzyme were performed at 3°C. Frozen 
Ehrlich ascites tumor cells (287 gm.) were homogenized in a Waring 
Blendor with two liters of deionized water for 30 seconds. The resulting 
homogenate was stirred for one hour, and the cell debris was removed by 
centrifugation at 3,000 x g for 15 minutes. The precipitate was dis-
carded and the pH of the water extract was slowly adjusted to 5.25 with 
0.5 M acetic acid. The solution was stored overnight, and then centri-
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fuged at 5,000 x g f'or 15 minutes. The precipitate was di.scarded and 
the supernatant f'luid was stored f'or one week. A small inactive pre-
cipitate was f'ormed and was discarded: ammonium sulf'ate crystals were 
then slowly added with mechanical stirring to a concentration of' 30% 
of' saturation and stirring was continued f'or 20 minutes. The resulting 
precipitate was discarded, and the ammonium sulf'ate concentration was 
increased slowly to 50% of' saturation with stirring. Af'ter 20 minutes 
of' stirring, the precipitate was collected, dissolved in 33 ml. of' 
distilled water and stored for two months at -l0°C without loss of 
activity. A resume of this procedure appears in Table I. 
D. Preparation of DEAE Cellulose for Chromatography 
DEAE cellulose, type 40, was suspended in water, allowed to settle 
for 20 minutes and decanted. This was repeated three times, followed 
by filtering. This DEAE cellulose was suspended in 4 volumes of 0.5 M 
NaCl, allowed to stand for one hour and then filtered. This was re-
peated twice. The DEAE cellulose was washed with 4 one-liter volumes 
of water, and then it was re-suspended in 3-4 volumes of a solution of 
0.1 M NaOH and 0.1 M disodium EDTA. The slurry was stirred constantly 
for l/2 hour, then filtered and washed with distilled water until the 
pH of the f'iltrate was between 6 and 7. The DEAE cellulose was resus-
pended in 3-4 volumes of 0.1 M Tris-HCl buffer pH 8.5, equilibrated 
overnight, filtered and resuspended in 0.01 M Tris-HCl buffer pH 8.5 
' 
several times until the pH was constant and the resistance was greater 
than 3,600 ohms. The column was regenerated by repeating this procedure, 
beginning with the NaOH-EDTA step. 
Table I 































*one unit= that amount of enzyme which gives an optical density 
change of 1.000 per minute. 
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E. The Purification of the Enzyme on DEAE Cellulose 
The crude enzyme preparation was dialyzed against 500 volumes of 
0.01 M of Tris-HCl buffer pH 8.5 for two hours. The buffer was then 
replaced and the dialysis was continued for 16-18 hours. Twenty ml. 
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of the dialyzed enzyme was adsorbed onto a column 20 X 120 mm. packed 
under a water pressure of 2700 psi. The column was washed with 80 ml. 
of the starting buffer. At this point the adsorption of the eluate at 
280 millimicrons was less than 0.030. The enzyme was then eluted with 
0.01 M NaCl and 0.01 M Tris-HCl buffer pH 8.5 (see Figure 1). The peak 
fractions (41-51) were collected and dialyzed against a neutralized, 
saturated ammonium sulfate solution for 16 hours at 4°C. Before being 
assayed, the crystallized enzyme was centrifuged and redissolved in 
0.01 M Tris-HCl buffer pH 8.5. For other experiments the enzyme was 
dissolved in the starting buffer and was dialyzed against two changes 
of the same buffer in order to remove traces of ammonium sulfate. 
F. Properties of the Enzyme 
1. Electrophoretic Homogeneity--The electrophoretic pattern of 
a solution of crystallized Ehrlich ascites LDH was developed on a starch 
gel block 25 x l X 0.5 em. at pH 8.5 in 0.167 M Tris-boric acid buffer 
at 3°C for 17 hours at 250 volts, 8 milliamperes (103). The purified 
enzyme protein was detected on l/2 of the starch gel block with amido 
black 10 B dye as a sharp, well-defined spot 2.9 em. on the anodal side 
of the origin. The other half of the starch gel block was sprayed wi.th 
a solution of 3AcPyAD-0.4 mg./ml. and 0.08 M Li lactate in 0.1 M Tris-
HCl buffer pH 8.5 and examined under an ultraviolet lamp. The fluorescent 
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Figure l. Chromatography of Ehrlich Ascites Carcinoma Lactic Acid 
Dehydrogenase on DEAE Cellulose. 
Protein, 365 mg. containing 490 units of activity, 
was applied to a column (22 X 40 em) which was equi.-
li.brated 0.01 M Tri,s-HCl buffer pH 8.). Fractions of 
3 ml. were collected at a flow rate l ml./mi.n. 
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cipitate and the DEAE cellulose purified preparation. 
2. Ultracentrifugal Homogeneity--Ultracentrifugal analysis of 
crystallized Ehrlich ascites LDH in 0.05 M sodium phosphate buffer pH 
7.08 is shown in Figure 2. Two major co~onents are present, one with 
a sedimentation coefficient of 1.9 s, and one with a sedimentation 
coefficient of 7.3 s. A moving partition-separation cell was used to 
separate these two co~onents. An analysis of their activity in Table 
II shows that the 7.3 S component is the active enzyme. A co~arison 
of the turnover numbers of the starting mixture and the 7.3 S fraction 
indicates that the specific activity increased, and that this was 
primarily due to the removal of inactive protein--1.9 S component. 
3· Ultraviolet Absorption Spectra--The spectra of the 1.9 S com-
ponent, the 7.3 S component, and the starting mixtUre are shown in 
Figure 3· All three s~les possess a typical protein spectrum with a 
maximum at 280-282 J!!l.., a shoulder at 290-292 J!!l.., and a minimum at 
250-252 J!!l.. The 280/260 ratio of the 7.3 S component was the lowest 
and indicated that a 260 J!!l.• absorbing material was associated with 
the 7.3 S co~onent. 
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)j. Influence of pH--Suspensions of the crystalline Ehrlich ascites 
lactic acid dehydrogenase i.n saturate ammonium sulphate pH 7. 0 were 
0 
stable at -10 C for at least six months. However, dilution of the 
enzyme in 0.1 M sodium phosphate buffer pH 7.0 caused an initial rapid 
reduction in turnover number which continued slowly when the enzyme was 
stored at 3°C for seventeen hours (Figure 4). The pH activity rela-
tionship was determined using the standard assay procedure and sodium 
phosphate buffer at varying pH levels. The enzymatic activity was 
Figure 2. Ultracentrifuge Schlieren Pattern of Purified Ehrlich 
Ascites Carcinoma Lactic Acid Dehydrogenase. 
0.59% solution in 0.05 M sodium phosphate buffer 
pH 7.1, after sedimenti.ng for 70.8 minutes at 59,780 
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Figure 3· Ultraviolet Absorption Spectra of Purified Crystalline 
Ehrlich Ascites Carcinoma Lactic Acid Dehydrogenase 
before and after Ultracentri.fugation in the Moving-
Partition Separation Cell (Fig. 2). 
Table II 
Resume of Results from Mov:Lng Partiti.on - Separation Cell 
Volume Sedimentation 280/260 Total optical Total change in 
coefficient of density at optical density 
major component 280 JTtl. at 340 JTtl./min. 
Before 
ultracentrifugation 0.7 1.88 6.195 4284 
After 
ultracentrifugation 
upper fraction 0.18 1.9 + 0.2 2.27 0.243 0 
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Figure 4. The Effect of Dilution in 0.1 M Sodium Phosphate Buffer 
pH 7 .l on the Activity of Crystalline Ehrlich Ascites 
Carcinoma Lactic Acid Dehydrogenase. 
The enzyme was diluted and stored at 0° - 2°C. The 
enzymati.c acti.vity was assayed using the s tandard system 
immediately after dilution ( • ), 5 minutes after dilu-
tion (x ), 17 hours after dilution (0) and 19 hours after 
dilution (~). 
optimal from pH 7 to 7.3 (Figure 5). 
5. Kinetics--The K determined at 22°C. and at pH 7.1 in m(pyr) 
0.1 M sodium phosphate buffer, 0.136 milli M NADH2 at a concentration 
of enzyme of 0.024 gm./ml., and at concentration of pyruvate from 
6.7 X 10-5M to 2.0 X 10-3 M was 8.3 X 10-5M (Figure 6&). High con-
centrations of pyruvate (Figure 6&) inhibited the enzymatic activity 
slightly. The Km(NADH
2
)' determined in the same manner keeping the 
pyruvate constant at 2 x 10-4M, was 1.3 X 10-5M (Figure 6B). Both 
values are in fair agreement with the values for lactic dehydrogenase 
from other sources (58, 72, 87, 129). 
The Km(lac)ts were determined in the presence of NAD, 3-AcPyAD, 
NHxD or thio-NAD at 22°C. and at pH 8.9 in 0.1 M dibasic potassium 
phosphate (Table 3, Figure 7). All analogs were employed at a final 
concentration of 0.5 mg. per 3.0 ml. of assay mixture. The enzyme 
concentrations which were employed are indicated in Table III. These 
K rs are also in fair agreement with those reported for lactic acid 
m 
dehydrogenases from other sources (71, 72, 87, 129). The analog ratios 
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as suggested by Kaplan (51) and Cahn et. al. (18) have also been calcu-
lated for the Ehrlich ascites carcinoma lactic acid dehydrogenase (Table 
IV). A comparison of these values (Expt. II) with those for mouse 4H 
and 4M parent lactic acid dehydrogenases indicates that this enzyme is 
of the 4M type. 
The variation of the numerical values of these ratios from those 
reported by Kaplan and Cahn was due to the variation in assay con-
ditions (Figure 8). This graph shows that the rate of reaction with 
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Figure ). The Effect of pH on the Activity of Crystalline Ehrlich 
Ascites Carcinoma Lactic Acid Dehydrogenase. 
The enzymatic activity was determined using the 
substrate and enzyme concentrations of the standard 
assay system and 0.1 M sodium phosphate buffer ( • ) or 
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Figure 6. Reciprocal Plot Showing the Change in Initial Velocity (M min-l X 10-1) at 22°C 
as a Function of Pyruvate Concentration (A) and as a Function of NADH2 Concen-
tration (B). 
The reaction mixtures contained 0.1 M sodium phosphate buffer pH 7.1, 0.024 
mg.jml. enzyme, and 1.30 X 10-4M NADH2 (A) or 2.0 X 10-4 M pyruvate (B). All 




































K determined in 0.2 M lactate 
m(analog) 












10 20 30 40 50 90 70 80 90 100 














[NAD ANALOG l X 104 
2.0 
Figure 7. Reciprocal Plot Showing the Change in Initial Velocity (6A min-1 ) at 22°C as a 
Function of Lactate Concentration (A) and as a Function of NAD or NAD Analog 
Concentration (B). 
The reaction mixtures contained 0.1 M KH2Po4, 2.31 X 10-4 M NAD (A) or 
0.2 M lactate (B). The enzyme concentrations used are those listed in Table III 
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Figure 8. The Effect of Lactic Acid Dehydrogenase Concen-
tration on the Rate of Reduction of 3 AcPyAD and 
ThioNAD. 
The reaction mixture consisted of 0.1 M di.-
basic potassium phosphate, 0.5 mg. of the analog 
and 0.013 M Li lactate. The rate of reduction 
(~/90t) was followed at 360 ~·for 3 AcPyAD and 
a 400 ~· for thioNA.D. The sources of enzyme are 
Ehrlich ascites carcinoma ( • •), mouse skeletal 










NAD Analog Ratios for Mouse Lactic Acid 
* Dehydrogenase (LDH) 
Expt. I Expt. II Li.terature 
Ehrlich Ehrlich Crude Crude Crude Crude 
ascites ascites skeletal heart skeletal heart 
LDH LDH nruscle nruscle nruscle nruscle 
LDH LDH LDH LDH 
0.32 0.59 0.57 0.21 1.20 0.48 
0.47 l. 70 5.6 





*The rates of analog reduction were determined at tbe enzyme concen-
trations summarized in Table III and then corrected to the same 
enzyme concentration. The subscript represents the concentration 
of either lactate or pyruvate at which the velocity was determined. 
l 1.3 X 10-2 
2 1.0 X 10-2 
3 3·3 X 10-4 
4 3.0 X 10-3 
5 3.0 X 10-4 
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that as the enzyme concentration was increased, the rate of reduction 
of 3 AcPyAD increased more rapidly than that of thioNAD. This re-
sulted in an increase in the ~h~~~D ratio. 
G. Source and Preparation of Normal Serum 
The serum used in the early experiments was obtained by cardiac 
puncture from three black rabbits and one albino rabbit. The blood 
was pooled and refrigerated for 24 hours. The clotted blood was then 
ringed and centrifuged. The resulting serum was decanted and stored 
0 
at -18 c. 
The second sample of normal serum, which·was used in the experi-
ments involving heated serum, was obtained from two albino rabbits of 
the same stock as those used for the preparation of the antiserum. 
This serum was removed from the rabbits and prepared in the same 
manner as the first.sample of serum. One half of the second sample 
of serum was heated to 56°C. for thirty minutes in the water bath of 
a slowly shaking Research Specialties incubator. This process inac-
tivated complement C1 2 (59). 
H. Preparation of Antiserum 
Each of two albino rabbits was immunized with l ml. of a 0.9% 
solution of purified enzyme (preparation l) dissolved in 0.01 M Tri.s-
HCl buffer pH 8.5. Approximately 0.05 ml. was injected i.nto each toe 
pad of the animal's hind legs, and the remaining soluti.on (approxi.-
mately 0.5 ml.) was injected intramuscularly into the hind leg. 
After one month, 50 ml. of blood was removed by cardiac puncture. 
The blood was refrigerated for 24 hours, ringed, and centrifuged. 
0 The serum was decanted and stored at -18 c. 
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Six months later each of the rabbits was reimmunized. The solu-
tion used in this procedure was prepared by adding 7 mg. of purified 
enzyme (preparation 2) in 0.5 ml. of 0.5 M sodium phosphate buffer 
pH 7.0 to 7.5 ml. l% aluminum chloride and adjusting the pH to 6 
with 0.1 M sodium hydroxide. Each rabbit then received one ml. of 
the aluminum hydroxide suspension, via the ear vein, every second 
day for two weeks. At the end of the third week 50 ml. of blood was 
removed from Rabbit 3 by cardiac puncture. The serum was prepared 
by the same method as that used after the first immunization and was 
stored at -l8°C. Before titration the second antiserum (2B) was 
heated at 56° for 30 minutes. 
I. Titration of Antibody Activity 
Enzyme Activity Neutralization Test 
The following reagents were placed in 10 X 75 mm. tubes. 
l) 0.01 ml. of an enzyme dilution which, when diluted 
to 1.00 ml., caused a change in absorbance at 340 ~· uf 200 X lo-3 
units/9011 , in the standard lactic acid dehydrogenase assay system. 
2) Varying amounts of antiserum. 
3) Sufficient potassium phosphate buffer 0.1 M, pH 
7.5, to bring the total volume to 1.00 ml. 
The contents of the tubes were mixed thoroughly, incubated at 
4°c. for twelve hours, and centrifuged in an International centrifuge 
at 2500 rpm for ten minutes. The resulting supernatant fluid was 
decanted, and 0.02 ml. of it was assayed in the standard LDH assay 
system. 
J. Preparation of Other Mouse Tissue Lactic Acid Dehydrogenases 
for Antiserum Specificity Studies 
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Except for the mouse skeletal muscle band A lactic acid dehydro-
genase all preparations of other tissue lactic acid dehydrogenase 
were obtained by homogenizing the tissue in 0.25 M sucrose and re-
moving the cell debris by centrifugation at 700 x g for 5 min. The 
supernatant fluid was decanted and 0.1 - 0.2 ml. was added to buffer 
and 0.04 or 0.08 ml. of antiserum. The precipitin test procedure 
was followed and the number of units of lactic acid dehydrogenase 
activity inhibited by 0.04 ml. of antiserum was compared. 
K. Antiserum Activity and Specificity 
The rabbit antiserum which was obtained after the completion of 
each immunization schedule was titrated against crystalline antigen. 
Rabbit A died of natural causes during the course of rei.mmunization, 
hence only the data on rabbit B is reported herein. The titration 
of antisera lB and 2B is summarized in Figures 9 and 10 respectively 
and indicates that antiserum 2B contained 3 times more antibody. 
Figure 10 also shows that antiserum 2B inhibited mouse skeletal muscle 
lactic acid dehydrogenase and Ehrlich ascites carcinoma lactic acid 
dehydrogenase equally well. These results were further confirmed by 
Levine and Cunningham (65) using the complement fixation test 
(Figure 11). Antiserum lB was titrated against crystalline Ehrlich 
ascites carcinoma lactic acid dehydrogenase and antiserum 2B against 
mouse skeletal muscle lactic acid dehydrogenase. A three to fourfold 
increase in antibody titer was observed. 
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Figure 9. Titration of Antiserum lB against Crystalline 
Ehrlich Ascites Carcinoma Lactic Acid Dehydrogenase 
by the Enzyme Activity Neutralization Test. 
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Figure 10. Titration of Antiserum 2B against Crystalline 
Ehrlich Ascites Carcinoma Lactic Acid Dehydro-
genase ( 0 ) and Mouse Skeletal Muscle Lactic 
Acid Dehydrogenase Band A ( 6 ) by the Enzyme 
Activity Neutralization Test. 
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Figure ll. Titration of Antisera lB and 2B by the Complement 
Fixation Test (65). 
Antiserum lB ( •) was diluted l/200 and titrated 
against crystalline Ehrlich ascites lactic acid de-
hydrogenase. Antiserum 2B (x) was diluted l/2000 
and titrated against mouse skeletal muscle lactic 
acid dehydrogenase ba nd A. 
The units are the same as in Figure 9. 
further support from experiments in which antiserum lB was tested 
as an inhibitor of lactic acid dehydrogenases from representative 
mouse tissues (Table V). From these results it is evident that 
Ehrlich ascites carcinoma lactic acid dehydrogenase antiserum was 
not as effective against the hybrid enzymes of other tissues as it 
was against the 4M parent enzyme. It is also evident that this 
antiserum was least effective against heart muscle lactic acid 
dehydrogenase, the 4H parent enzyme. 
L. Maintenance of Tumor Lines 
Two sublines of the tumor were maintained at all times by 
transplantation every seven days. Transplantation consisted of 
sterile removal of l cc. of Ehrlich ascites carcinoma cell suspen-
sion from the peritoneal cavity. 0.1 ml. of thi.s suspension was 
injected intraperitoneally into each of five Swiss-Webster albino 
mice, and the remaining 0.5 ml. was diluted aseptically in 4.5 ml. 
of Hank's tissue culture medium. An aliquot of the diluted cell 
suspension was removed aseptically, diluted l/10 in buffered iso-
tonic formaldehyde solution and counted i.n a hemocytometer. Rou-
tinely, 12-16 X 106 cells were transplanted in 0.1 ml. of Ehrlich 
ascites carcinoma cell suspension. The Hank•s tissue culture 
medi.um suspension was used as a source of tumor in all experiments 
testing the growth rate of the tumor, and the in vivo effects of 
normal rabbit serum and anti-Ehrlich ascites lactic acid dehydro-
genase rabbit serum. 
M. Determination of Growth Rate of Ehrlich Ascites Carcinoma 
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Table V 
Inhibition of Crude Extracts of Lactic Acid 
Dehydrogenase from Mouse Tissues 
Tissue Source of Enzyme 















Antiserum 0.04 m./1.0 ml. total incubation mixture 
*one unit= a change in A340 ~ of 1.000/90 sec./0.02 ml. 
incubation mixture. 
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The growth rate of the tumor was determined in the following 
manner. 0.1 ml of the diluted Ehrlich ascites cell suspension of 
known concentration (1-2 X 106 cells) was injected intraperitoneally 
into Swiss-Webster albino mice weighing 18-20 grams. The tumors 
were harvested after 72 or 144 hours into isotonic buffered for-
maldehyde solution by the following procedure (49). 
1. Coruwosition of Isotonic Buffered Formaldehyde Solution pH 7.0 
12.5 gm. NaH2Po4 
19.5 gm. Na2HPo4 
300 ml. 30% formaldehyde 
2700 ml. distilled water 
2. Procedure 
90 ml. of isotonic buffered formaldehyde solution was 
divided equally into three 250 ml. beakers. The mouse was killed 
by cervical flexure, pinned to a dissecting board, and swabbed with 
alcohol. A longitudinal incision was made in the skin along the 
entire ventral midline of the body. Four additional incisions 
were made perpendicular to the first incision out to each leg, care 
being taken not to pierce the abdominal muscles surrounding the 
peritoneal cavity. The mouse was turned over and swabbed with 
alcohol. The incisions toward the hind legs were continued around 
the back. The skin was reflected to the neck, where it was cut 
and completely removed. The head of the mouse was placed between 
the first and second fingers and the tail between the thumb and 
first finger. The peritoneal cavity was opened over one of the 
three beakers. The abdominal organs were washed thoroughly i.n the 
solution in the first beaker, then in the second, and finally in the 
third. The solution in the beakers was then combined in a 100 ml. 
graduate, the volume was brought to 100 ml., and the graduate was 
covered with aluminum foil. In this solution the cells kept their 
cytological characteristics for at least 24 hours. 
After the tumor from each mouse in a given experi.ment had been 
harvested and collected in a separate graduate, the total number of 
cells in each graduate was determined in the following manner. The 
cells in each graduate were resuspended by shaking vigorously, and an 
aliquot was counted in a hemocytometer under a microscope at a 230 fold 
magnification. The number of cells in a 0 .l cubic mm. field of each of 
two chambers was counted, averaged, and multiplied by 106 to give the 
total growth of the tumor. This count included only those cells which 
were 20-30 microns in diameter, and which contained a large round 
nucleus and a small peripheral band of cytoplasm. 
N. Assay of In Vivo Anti-tumor Activity 
Normal rabbit serum and Ehrlich asci.tes carcinoma lactic acid 
dehydrogenase antiserum were tested for their direct and indirect 
effects on tumor cell growth. The direct effect was measured by 
mixing the Hank's tissue culture medium cell suspension (1.3- 1.8 x 
106 cells per 0.1 ml.) with the desired volume of serum or antiserum, 
and injecting the resulting suspension intraperitoneally into each of 
eight mice. This will be designated as the Neutralization Test (131). 
The indirect effects of the normal serum and antiserum on cell 
growth was assessed by two methods. The fi.rst method, the passive 
immunity test (131), consisted of injecting the Hank's tissue culture 
medium suspension of 1.3 - 1.8 X 106 cells intraperitoneally into 
each of eight mice, and immediately thereafter injecting the serum or 
antiserum subcutaneously. The second method combined tests of tox-
icity and preimmunizati.on. The serum was injected subcutaneously 
into 6-8 mice. Twenty-four hours later the animals were challenged 
with an intraperitoneal injection of a Hank•s tissue culture medium 
suspension of 1.3 - 1.8 X 106 cells. Thus the first part tested 
toxicity and the second tested the possibility of immediate pre-
immuni.za tion. 
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In every experiment the tumor was permitted to grow for 72 hours, 
at which time four animals from each group were sacrificed, the tumors 
were harvested, and the total number of tumor cells in each mouse was 
determined in the manner described on pages 50 and 51. The remaining 
four animals were maintained until death in order to estimate the 
average survival time of infected mice. 
Each experiment consisted of a control group of mice which 
received only tumor and several groups which were treated with 1.3 -
1.8 X 106 Ehrlich ascites cells and/or various amounts of serum or 
antiserum. 
0. The Effect of Normal Serum and Antiserum on the Growth of 
Ehrlich Ascites Carcinoma in Mice 
During the early experiments both growth and survi.val time were 
measured. Although the animal survival time i.s often used as the 
primary index of tumor growth it is apparent from a comparison of the 
data in Table VI with that in VII that the direct measurement of 
the number of cells in the peritoneal cavity is a far more sensitive 
Table VI 
Effect of Various Sera on the Survival of Mice Bearing 
Ehrlich Ascites Carcinoma 
(Mice Received 0.4 ml. Sera Mixed with Ascites Cells) 
Temperature l Mean Survival Time - Days (Range) 
of Serum-Cell 
Mixture Before 
Injection No Serum Normal Serum Normal Serum Heated to 
oc 56°c. for 30 
min. 
18 - 22 17 (12-22) 16 (l)-16) 
18 - 22 10.7 ( 9-13) 15 (12-18) 
18 - 22 12.8 (12-14) 11.5 (10-13) 12.8 (ll-14) 
0 12.0 14.8 (12-21) 12.3 (13-14) 
~our mice per group. 
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Table VII 
Effect of Various Sera on the Number of Cells in the 
Abdominal Cavity of Mice Bearing Ehrlich Ascites 
Carcinoma 
(Mice Received 0.4 ml. Sera Mixed with Ascites Cells) 
Temperature 




18 - 22 
18 - 22 
18 - 22 
0 










10 ( 6-19) 
21 (l5-37)b 
Normal Serum 
He a ted to 56 °C • 
for 30 min. 
70 (45-81) 
26 (ll-38)b 
~our mice per group. 
bThese values are low due to a low initial inoculum 1.5 X 106 
cells. The usual inoculum was 1.35 to 1.45 X 106 cells and 
the interexperimental variation in the "no serum" controls 
in this table and in subsequent tables reflects the vari.ation 
i.n the size of the initial inoculum. 
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and direct index of cell growth. 
The growth rate of the Ehrlich ascites carcinoma was estimated 
seventy-two and one hundred and forty-four hours after implantation 
(Figure 12). A comparison of this data with that of Kline and 
Revesz (55) indicates that the rate of growth of both tumors is 
almost identical, as both possessed a generation time of approxi-
mately twelve hours. Furthermore, the suspension of the Ehrlich 
ascites carcinoma in Hankts tissue culture medium appeared to cause 
the growth curve to shift one day, apparently eliminating the lag 
period. Since the growth rate appeared to depart partially from 
the initial logarithmic phase after seventy-two hours, this period 
was chosen as the point at which the tumor growth was assessed in 
all the experiments testing the immune effects of normal serum and 
antiserum. 
Before assessing the effect of the pooled normal rabbit serum 
I on the growth of Ehrlich ascites carcinoma, this serum was in-
jected into normal mice in order to determine the maximum non-toxic 
dose. The normal serum was administered either subcutaneously or 
intraperitoneally in doses of 0.1, 0.5 and 1.0 ml. No untoward 
effects were observed when the subcutaneous route was employed, 
however the mice which were treated intraperitoneally showed a 
slight diarrhea when they received 0.5 ml. of normal serum and ex-
treme diarrhea when they received 1.0 ml. of normal serum. Because 
of this toxicity the normal serum and antiserum were tested at 
doses of 0.5 ml. or less. Finally, the growth of the tumor was not 
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Figure 12. Growth Rate of Ehrlich Ascites Carcinoma in Swiss 
Webster Albino Mice. 
( • ) data of Kline and Revesz (55); (x) data 
of tumor used for this thesis. 
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peritoneally with normal serum twenty-four hours before the implan-
tation of the Ehrlich ascites carcinoma. 
Before the antiserum was tested the validity of the methodology 
was assessed with normal serum. The data in Table VIII shows that 
in the passive immunity test doses of normal serum up to 0.5 ml. 
per mouse did not inhi.bit the growth of the tumor. In the neutrali-
zation test (Figure 13) a graded cytotoxic effect was exerted on the 
tumor cells by normal serum, 0.2-0.5 ml. per mouse. This effect was 
eliminated by incubating the normal serum at 56°C for thirty minutes 
or by maintaining the serum-cell mixture at 0°C (Table VI). These 
procedures respectively inactivated complement (cr 2) and reduced the 
rate of the complement requiring cytotoxic reaction. 
In order to separate the nonspecific cytotoxicity of the rabbit 
serum from any specific effect of the antiserum, the C1 2 was inacti-
vated before testing the serum and antiserum by incubation at 55°C 
for thirty minutes. This procedure did not modify the ability of 
the antiserum to inhibit the enzymatic activity as was i.ndicated by 
the posi.tive enzymatic activity neutralization test of antiserum 2B 
(Figure 10). Furthermore when complement was added back to the 
system for the complement fixation assay (Figure ll) the increased 
activity of antiserum 2B over lB was almost identical to that 
observed in the enzymatic activity neutrali.zation test. 
Finally the fact that only male mice were used in these experi-
ments is substantiated by the evidence in Table IX which indicates 
that the sex of the host does not affect the growth rate of the 
Ehrlich ascites carcinoma. 
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Table VIII 
In Vivo Effect of Normal Serum on the Number of Cells 
in the Abdominal Cavity of Mice Bearing the Ehrlich 
Ascites Carcinoma Using a Passive Immunity Test 
Expt. Amount of Number of Mice Mean Number gf 
Normal Serum Cells x lo-
(Range) 
I 0 4 68 (58-82) 
0.1 4 70 ( 63-81) 
II 0 2 71 (57-85) 
0.5 4 54 (43-65) 
III 0 4 59 (50-78) 
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Figure 13. The Effect of Normal Serum on the Growth of Ehrlich 
Ascites Carcinoma before and after Heating at S0°C 
for 30 Minutes Utilizing the Neutralization Test. 
(0,~) Normal serum l; (x) Normal Serum 2; 





Effect of the Sex of the Mouse on the Number of Cells 
in the Abdominal Cavity of Mice Beari.ng Ehrlich Ascites 
Carcinoma 
Mean Number of Cells per Mouse X 10 
(Range) l 
-6 
Sex No Serum Neutralization Test Passive Immunity Test 
0.1 ml. Normal Serum 0.1 ml. Normal Serum 
Male 68 (58-82) 58 (51-67) 70 ( 63-81) 
Female 51 (26-70) 49 (32-61) 69 (54-76) 
~our mice per group. 
Having established the conditions necessary for the removal of 
the cytotoxic factor present in all rabbi. t sera, the antitumor 
activity of antiserum 2B was tested at doses of 0.1 and 0.4 ml. per 
mouse. The larger dose was not toxic to the mice nor did it induce 
immunity when injected twenty-four hours before tumor implantation 
(Table X). Both the neutralization test and the passive immunity 
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test indicate that the size of the total cell population in the 
abdominal cavity after 72 hours of growth was not extensively 
modified by either the high or the low dose of antiserum 2B (Table X). 
Therefore, under the conditions outlined herein the antiserum does not 
appear to be an effective antitumor agent. 
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Table X 
Effect of Antiserum 2B on the Number of Cells in the 
Abdominal Cavity of Mice Bearing Ehrlich Ascites 
Carcinoma 
Expt. Amount of Number of Type of Test a Mean Number of 
Antiserum Mice Cells per Mouse 
x lo-6 (Range) 
I 0 4 58 (47-76) 
O.l 4 Neutralization 67 (58-83) 
O.l 4 Passive Immunity 64 (50-93) 
II 0 4 54 (42-64) 
0.4 4 Neutralization 48 (29-90) 
0.4 4 Passive Immunity 64 (42-54) 
III 0 4 53 (40-64) 
0.4 4 Antiserum injected 46 (30-59) 
intraperitoneally 
one day before 
tumor 
aNeutralization Test - Antiserum mixed in vitro with initial 
inoculum. 
Passive Immunity Test - Antiserum administered subcutaneously. 
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III. DISCUSSION OF RESULTS 
The results presented in this thesis support previous fi.ndi.ngs 
which demonstrated that there were no kinetic or antigenic differ-
ences between tumor lactic acid dehydrogenase and skeletal ~~scle 
lactic acid dehydrogenase (58). However, they also indicate that 
the Ehrlich ascites carcinoma lactic acid dehydrogenase i.s different 
from mouse skeletal muscle lactic acid dehydrogenase in electro-
phoretic mobi::.i.ty. 
Ehrlich ascites tumor lactic acid dehydrogenase has been purified 
200 fold from the tissue homogenate. The presence of a numl:er of i.so-
zymes in a large number of tissues has been adequately documented (37, 
')6, 97, 123). However, electrophoretic analysis of this enzyme prepa-
ration at pH 8.6 on starch gel yielded a single protein band which 
coincided with the band of enzymatic activity. Since these conditions 
were almost identical to those used for the demonstration of isozymes 
in the organs of many other animals (181 and identical to those used 
for the separation of other mouse organ LDH•s (50a), it is reasonable 
to conclude that there is only one isozyme present in this enzyme 
preparation. 
The separation cell ultracentrifugal analysis of the Ehrlich 
ascites tumor lacti.c acid dehydrogenase i.ndicated that the enzyme 
preparation consisted of 
mentation coefficient of 
two major components: one (A) with a sedi.-
-13 1.9 X 10 sec. and the other (B) with a 
sedimentation coefficient of 7.3 X lo-13 sec. The enzymatic activity 
was associated only with the 7.3 S component. The sedimentation co-
efficient of this fraction was in agreement wi.th that reported for 
other lactic acid dehydrogenase (38, 44, 73, 74, 84, 86). The 1.9 S 
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component was inactive. It had an ultraviolet spectrum and a 280/260 
ratio characteristic of proteins, and its sedimentation coefficient was 
of the same order of magnitude as the subunit of beef heart lactic acid 
dehydrogenase, 1.75 S (3). Furthermore, the activity of the Ehrlich 
ascites carcinoma lactic acid dehydrogenase decreased rapidly after 
dilution in 0.1 M sodium phosphate buffer, pH 7.0, indicating inac-
tivation of the enzyme. This inactivation could conceivably be due to 
the dissociation of the enzyme into its subunits in dilute solutions. 
The ultraviolet absorption spectrum of Ehrlich ascites tumor 
lactic acid dehydrogenase was the same a·s that of other lactic acid 
dehydrogenases (10, 58, 87) with a maximum at 278 ~ and a shoulder 
at 290-292 ~· The 280/255 ratio of the 7.3 S comppnent was 1.72, 
which was lower than that of the mixture (Figure 3) and much lower 
than the values reported for other highly purified lactic acid dehydro-
genases, 2.58 to 2.65 (10, 58, 87). The reduction in this ratio may be 
the result of bound NAD as is the case with glyceraldehyde 3 phosphate 
dehydrogenase (109) and bovine heart muscle lactic acid dehydrogenase 
(105). However, the conclusive identification of bound NAD in this 
Ehrlich ascites tumor lactic acid dehydrogenase preparation requires 
further investigation. 
If, on the basis of the ultracentrifugal data, the molecular 
weight of the enzyme is assumed to be 135,000, then under the stated 
assay conditi.ons, the approximate turnover number for the purified 
enzyme is 37,000. This is also of the same order of magnitude as the 
turnover numbers of other crystallized animal lactic acid dehydrogenases 
(10, 56, 58, 83, 97). Fi.nally, if the turnover number of the 7.3 S 
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component (Table II) is corrected for contamination with the 1.9 S 
component, it becomes 34,700. This value agrees wi.th the turnover 
number calculated from the data i.n Table I for the material obtained 
from the DEAE cellulose column and provides additi.onal evidence for the 
fact that the l. 9 S component i.s the subunit of the enzyme rather than 
an inactive contaminant. 
The kinetic data (Fig. 5 and 7) and the analog ratios (Table IV) 
indicate that the Ehrlich ascites carcinoma lactic acid dehydrogenase 
is similar to the 4 M form of mouse lactic acid dehydrogenase, the 
predominant enzyme form in skeletal muscle. The relatively slight 
inhibition by high concentrations of pyruvate is similar to that re-
ported for the skeletal muscle lactic acid dehydrogenases of humans 
(97), chickens 08), pigs (50), and rats (58) and the close agreement 
between the analog ratios of Ehrlich ascites carcinoma lactic acid 
dehydrogenase and mouse skeletal muscle lactic acid dehydrogenase con-
firms the closeness of the nature of the Ehrlich ascites carcinoma 
lactic acid dehydrogenase to the 4 M parent form. 
The variability observed among the analog ratios in experiment I, 
experiment II, and those reported by Cahn ~ al. (18) and Kaplan et al. 
(51) appeared questionable at the outset. However, experiment II, 
which was carried out in Dr. Kaplan•s laboratory, confirms the simi-
larity between mouse skeletal muscle lactic acid dehydrogenase and 
Ehrlich ascites carcinoma lactic acid dehydrogenase. These data also 
suggest that the deviation of the ratios of experiments I and II from 
those reported by Kaplan et al. (51) and Cahn et al. (18) are merely a 
function of slight variations in assay procedure, particularly the 
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enzyme concentration, and not the result of different enzymes. 
Finally, if the isolated lactic acid dehydrogenase and the tumor 
lactic acid dehydrogenase are identical, the abnormally fast glycolytic 
rate can be partially explained by the fact that the tumor lactic aci.d 
dehydrogenase is of the muscle type and therefore, is not very strongly 
inhibited by high amounts of lactic acid or pyruvic acid. This would 
then permit a large rate of anaerobic glycolysis, the value of which 
is directly proportional to the lactic acid production. As the heart 
type is approached, the substrate inhibition becomes more pronounced 
and the rate of lactate formation, as well as the total amount of 
lactic acid, is reduced. The combination of the lactic acid dehydro-
genase type with that of absolute enzyme concentration could conceiv-
ably account for the wide variation values summarized in the 
tables of Aisenberg (l). 
A comparison of the electrophoretic mobility of the Ehrlich 
ascites carcinoma lacti.c acid dehydrogenase to that of mouse skeletal 
muscle lactic acid dehydrogenase (18) shows that the Ehrlich ascites 
carcinoma lactic acid dehydrogenase migrates slowly toward the anode, 
whereas the mouse skeletal muscle lactic acid dehydrogenase migrates 
slowly toward the cathode. This could indicate either the presence of 
a different amino acid sequence in some part of the enzyme molecule 
other than those parts necessary for the enzymatic properties, or it 
could indi.cate the existence of fewer carboxamide groups. This aspect 
of the problem requires further investigation. Regardless of the 
nature of the difference, it is evident that the difference exists and 
that i.t might be great enough to initiate the formation of a specific 
antibody, different from that elicited by mouse skeletal muscle 
lactic acid dehydrogenase. 
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The rabbit anti-Ehrlich ascites carcinoma lactic acid dehydro-
genase serum was then developed using the purified enzyme as the 
antigen. A comparison of the antibody titers of antiserum lB and 
2B to those of antisera developed by other investigators (Table XI) 
indicates that these antisera are respectively approximately 20 and 
60 times more potent. Antiserum lB was used for the study of the 
specificity of the antiserum, and 2B was used for the study of the 
antitumor activity. 
It is important to note that the lactic acid dehydrogenase 
activity was inhibited by the antiserum which was heated to 56° for 
30 minutes. This procedure inactivates complement C' 2• Therefore, 
the results indicate that the Ehrlich ascites carci.noma lactic acid 
dehydrogenase antiserum exerts its inhibitory effect in the absence 
of a complete complement system. That is, it is complement independent, 
and it may be related to the complement independent antibodies of the 
rabbit anti-supernatant serum prepared and studied by Horn (47). 
The enzyme neutralization test and the complement fixation test 
indicated that the antiserum was as specific for Ehrlich ascites car-
cinoma lactic acid dehydrogenase as it was for mouse skeletal muscle 
lactic acid dehydrogenase band A. Furthermore, the antiserum was much 
less effective against the other hybrid forms of mouse lactic aci.d 
dehydrogenase which are distributed in various amounts in different 
tissues throughout the body. These results are in agreement with the 
kinetic data and the analog ratios and together they support the 
Table XI 
Compari.son of the Antibody Activity of Various Lactic Acid Dehydrogenase Antisera 
illH % Inhibition Total Enzyme Total Antiserum Time of 
Concentration Concentration Incubation 
llg· ml. 
Human Heart 90 l 0.2 24 hr. 
Human Liver 90 l 0.2 24 hr. 
Jensen Sarcoma 56 2 1.2 10 mi.n. 
Rat Skeletal Muscle 56 2 1.2 10 min. 
Ehrlich Ascites Carcinoma lB 50 10 0.085 24 hr. 
lB 50 6.7 0.055 24 hr. 
2B 50 6.7 0.020 24 hr. 
lB 90 6.7 0.085 24 hr. 









hypothesis that the Ehrlich ascites carcinoma lactic acid dehydrogenase 
is enzymatically similar to mouse skeletal muscle lactic acid dehydro-
genase bandA. This is in full agreement with the results of Kubowitz 
and Ott (58) which indicated that no difference existed in the speci-
ficity of Jensen sarcoma lactic acid dehydrogenase and rat skeletal 
muscle lactic acid dehydrogenase for their own or opposite antiserum. 
The apparent equal specificity of the antiserum for the Ehrlich 
ascites carcinoma lactic acid dehydrogenase and the mouse skeletal 
muscle lactic aci.d dehydrogenase band A also suggests that although 
there may be a difference in composition between these two enzymes, 
as indicated by the difference in electrophoretic mobility, this 
structural difference was not sufficient to stimulate the formation 
of detectably different antibodies. 
Although there appeared to be no difference in antiserum speci.-
ficity between the tumor lactic acid dehydrogenase and the skeletal 
muscle lactic acid dehydrogenase, the antiserum was tested for anti-
tumor activity. Of particular interest were the results of the 
neutralization test, since this tested the ability of the antiserum 
to react with the tumor cells and to inhibit directly the growth of 
the tumor. 
The growth properti.es of the tumor itself appear to be very 
similar to those reported by Kline and Revesz (55). The apparent 
increase in the growth rate is probably either the result of the use 
of Hankt s tissue culture medium instead of a physiologi.cal saline 
solution, the result of the bioassay method which more accurately 
measured the total cell population or the inclusion of histiocytes 
which were cytologically very similar to the tumor cells when viewed 
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unstained in the hemocytometer. The generation time for both lines 
of the Ehrli.ch ascites tumor was twelve hours if the lag period of the 
line used in these experiments is assumed to be very small. The close 
agreement of the 144 hour value with that of Kline and Revesz (55) 
further supports the similarity of these tumor lines. For the assay 
of the biological activity of the antiserum, the seventy-two hour 
period was selected as the end point for the measurement of possible 
inhibition of the tumor. This point in the growth curve was char-
acterized by a 40 fold increase in cell count and represented the 
largest possible growth during the second phase of growth (logarithmic 
phase), It was also a convenient point to measure the total number of 
cells without further dilution. 
Both the direct and i.ndirect effects of the antiserum on the cell 
were measured, the former by the neutralization test, and the latter 
by the passive immunity test. The reliability of both tests was first 
assessed with normal serum. The results demonstrated that normal 
serum did not alter tumor growth in the passive immunity test. However, 
when normal rabbit serum was mixed directly with the tumor cell sus-
pension, a graded cytotoxicity, which was a function of the amount of 
serum, was observed. This cytoxic action was eliminated either by 
"6° 0 b heating the serum at / for 3 minutes, or y maintaining the serum 
cell suspension at 0°C. These procedures inactivated complement c1 2 
and the results fully support those of Landy et al. (59), Lumsden et al. 
(67), Green et al. (42) and Willheim (126). As a result of this, all 
the antisera were heated to 56° for 30 minutes before testing in order 
to avoid this universal cytotoxicity. 
The most important fact to be derived from this evidence is that 
the inhibition of cell growth is very easy to observe and quantitate 
under the experimental conditions. 
The results from the testing of the antiserum 2B were negative. 
7l 
The negati.ve results cannot be attributed to the heating process, 
since the enzyme activity was inhibited by antiserum, the complement 
system of which had been inactivated by heating to 56° for 30 minutes. 
The possi.bili.ty exists that no change in the total ascites cell 
population was observed because the inhibition of tumor cell growth 
was exactly balanced by an equal and opposite increase in the histio-
cyte popula ti.on. However, this appears to be unlikely for the 
following reasons. There was no apparent change in the cell popu-
lation when the initial inoculum was mixed with normal serum (Table 
VII), and there was no increase in the size of the cell population 
when the mice were pretreated with the antiserum (Table X). This 
indirectly indicates that the histiocyte populati.on was not modified 
by the antiserum. There was no difference between the effect of normal 
serum and of anti.serum on the size of the cell population. This 
hypothesis would require that the Ehrlich ascites carcinoma lactic 
acid dehydrogenase antibodies alone would inhi.bit the growth of the 
tumor cells and would stimulate an increase in the number of histio-
cytes. Since the Ehrlich ascites carcinoma lactic acid dehydrogenase 
antibodies are not completely specific for Ehrlich ascites carcinoma 
lactic acid dehydrogenase, it seems unlikely that the multi.plication 
of one cell population would be inhibited while another was stimulated. 
The effect of multiple injecti.ons of antiserum remains to be 
assessed to establish whether an inhibitory effect was masked by an 
increased rate of cell growth during the seventy-two hour experimental 
period. 
The apparent negative results may also be attributed to: 
1. the inability of the antiserum to penetrate the cell 
membrane. 
2. the ability of the cell to inactivate the antiserum 
activity. 
3. the ability of the cell to replace rapidly i.ts lost 
lactic acid dehydrogenase by the synthesis of new enzymes. 
4. the absence of an obligate requi.rement of lactic acid 
dehydrogenase for tumor metabolism. 
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5. the reaction of the antiserum with the lactic acid dehydro-
genase induced by the transmissible lactic acid dehydrogenase agent 
isolated by Riley et al. (101) from twenty-six different mouse tumors 
and shown to be different from the carcinogenic viruses. 
The inability of the antiserum to penetrate the cell membrane 
remains a possible explanation for the absence of inhibition of neo-
plastic growth. Goldberg and associates (31, 32, 39, 40, 41) have 
shown that ferritin-labeled cytotoxic antibodies to the Krebs ascites 
tumor become fixed to the surface of the Krebs ascites cells. These 
antigen-antibody complexes were eventually pinocytosed and could be 
identified in vesicles extending centrally from the outside. The 
vesicles were characterized by a nonuniformity of size and a smooth 
uniform 70 Angstrom membrane. Ferritin granules were not identifi.ed 
within the endoplasmic reticulum nor within the mitochondria. The 
questions remain: Was the Ehrlich ascites lactic acid dehydrogenase 
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antibody pinocytosed and degraded after reacting with its antigen at 
the membrane surface? Could the antiserum have even reached its 
antigen across the cell membrane? Was the antiserum taken up by the 
cell and degraded? These aspects of the problem are indeed intriguing 
and can be solved by using current labeling and purification methods. 
Despite the fact that oxamate, a specifi.c inhibitor of lactic 
acid dehydrogenase (90, 91, 93, 94), inhibits the growth of cultures 
of HeLa cells, the necessity of lactic acid dehydrogenase for con-
tinued in vivo cell growth, except possibly under strict anaerobic con-
di tions, remains questionable. Although the ascites fluid of the peri-
toneal cavity may be low in oxygen supply, it is probably not devoid of 
it. Hence, even i.f the lactic acid dehydrogenase were completely in-
hibited, there would probably be enough oxygen to supply the energy 
necessary to maintai.n the cell population until the cells could replace 
some of the inactivated lactic acid dehydrogenase--assuming the anti-
lactic acid dehydrogenase serum penetrated the cell and inactivated the 
cell lactic acid dehydrogenase. Confirmation of this explanation again 
depends upon a knowledge of the penetrability of the antiserum. 
The possibility of replacement of the inactivated enzyme receives 
some support from the fact that the Ehrlich ascites tumor exhi.bits a 
differential leakage of glycolytic enzymes into the medium (45, 132, 
133). This was apparently not a result of cell lysis or overt cell 
injury, since the cells remained viable accordi.ng to the lissamine 
green test and were more stable to centrifugation than strain L cells 
whi.ch did not release enzymes into the medium (45). This would then 
indicate that the tumor was constantly synthesizing the glycolytic 
enzymes and could easi.ly replace those enzymes inactivated by the 
antiserum. 
The inability of the antiserum to inhibit tumor growth may also 
be related to the fact (101) that the elevated lactic acid dehydro-
genase of many transplantable tumors was controlled by a passenger 
virus--a transmissible lactic acid dehydrogenase agent. It is con-
ceivable that the tetraploid tumor used in these experiments carried 
this agent, and that we have isolated the lactic acid dehydrogenase 
induced by this agent. Since this is a passenger virus and has no 
effect on tumor growth, the inhibition of this lactic acid dehydro-
genase would not effect the growth of the tumor. 
Finally, if the Ehrlich ascites tumor is not the result of a 
pure metabolic abberation, but of a viral infection as is suggested 
by Tolnai (106), then the logical approach would not be through the 
development of an antienzyme antiserum but an antiviral antiserum. 
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Ehrlich ascites carcinoma lactic acid dehydrogenase was isolated from 
an eleven-day old tumor by acid precipitation, ammonium sulfate fractiona-
tion, and chromatography on DEAE cellulose. Electrophoretic analysis 
indicated that the final enzyme preparation and the ammonium sulfate 
fraction contained a single isozyme, that is, one of the five possible forms 
of lactic acid dehydrogenase two of which are tetramers of a single but 
different protein while the other three are tetramer mixtures of both 
protei.ns (i.e. hybrid enzymes). Ultracentrifugal analysis indicated that 
the final enzyme preparation was composed of two major components with 
sedimentation rates of 7.3 Sand 1.9 S. The enzymatic activity was associ-
ated only with the 7.3 S component. The apparent loss of enzymatic activity 
in O.l M phosphate buffer pH 7.0 and the magnitude of the value of the 1.9 S 
component indicated that this represented the subunit of the enzyme. The 
of 1.3 X 10-5 M, -5 7.3 S component had a Km(pyr) of 8.3 X 10 M, a Km(NADH
2
) 
K Of l 27 X 10- 2 M and a K of l 38 X lo-4 M 
m(lac) • ' m(NAD) • • The ratios, 
~ 0.59 NADH2 4 and NADH 5 
2 
0.78, for the Ehrlich ascites carcinoma lactic 
acid dehydrogenase were identi.cal to the ratios for mouse skeletal muscle 
lactic acid dehydrogenase. 
Two i.dentical lots of enzyme were prepared and used to stimulate anti-
body formation in rabbits. Each rabbit was immunized with nine milligrams 
of the first lot of enzyme administered via the toe pads and intramuscularly. 
- 2 -
Six months later each rabbit was reimmunized intravenously with an alum 
suspension of seven milligrams of the second lot of enzyme. The titration 
of each antiserum by the enzyme activity neutralization test indicated that 
the antiserum was complement independent and that the antiserum obtained 
after reimmunization was three ti.mes more active than that obtained after 
the first immunization. These results were confirmed by the complement 
fixation test. Both tests also i.ndi.cated that the antiserum was equally 
specific for mouse skeletal muscle lactic acid dehydrogenase. This anti-
serum, when tested by the enzyme activity neutralization test was not as 
specific for the crude lactic acid dehydrogenases of mouse hepatoma, spleen, 
lung, and liver as it was for the purified Ehrlich ascites enzyme, and it 
was least effective against the mouse heart enzyme. These results indicated 
that the antiserum was specific for the 4M isozyme, the type found in 
skeletal muscle. 
The antiserum did not possess an in vivo antineoplastic activity when 
tested by the neutralization and the passive immunity tests. These results 
may be attributed to; the inability of the antiserum to penetrate the cell 
membrane; the cellular inactivati.on of the antiserum; the rapid replacement 
of the inactivated lactic acid dehydrogenase; the absence of an obligate 
requirement of lactic acid dehydrogenase for tumor metabolism; or the 
reaction of the anti.serum with the lactic acid dehydrogenase induced by the 
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